bluuebunny/crossref_metadata_2025_split huggingface dataset:
The methods and use of questionnaires for the diagnosis of dental phobia by Japanese dental practitioners specializing in special needs dentistry and dental anesthesiology: a cross-sectional study
Authors: Ogawa Mika , Ayuse Terumi , Fujisawa Toshiaki , Sato Shuntaro , Ayuse Takao 
Published: February 2022

Abstract
Background
Dental phobia is covered by medical insurance; however, the diagnostic methods are not standardized in Japan. Therefore, the aim of this study was to investigate the methods and use of questionnaires for the diagnosis of dental phobia by Japanese dental practitioners specializing in special needs dentistry and dental anesthesiology.

Methods
We conducted an online survey to obtain information from the members of the Japanese Society for Disability and Oral Health (JSDH, n = 5134) and the Japanese Dental Society of Anesthesiology (JDSA, n = 2759). Response items included gender, qualification, affiliation type, methods of diagnosis and management of dental phobia, use of questionnaire, need to establish standardized diagnostic method for dental phobia, and others. The chi-squared test was used to compare answers between the three groups: JSDH only, JDSA only, and both JSDH and JDSA. Multiple logistic regression analysis was conducted to identify factors associated with the use of an assessment questionnaire.

Results
Data were obtained from 614 practitioners (JSDH only, n = 329; JDSA only, n = 195; both JSDH and JDSA: n = 90, response rate: 7.8% [614/7,893], men: n = 364 [58.5%]). Only 9.7% of practitioners used questionnaires to quantify the level of dental anxiety. The members of both JSDH and JDSA group used questionnaires more frequently than members of the JSDH only (19% and 7.1%, respectively; Bonferroni corrected p < 0.01). Most practitioners (89.1%) diagnosed dental phobia based on patient complaints of fear of treatment. Furthermore, majority of the participants (73.3%) felt the need to establish standardized diagnostic method for “dental phobia.” Multiple logistic regression analysis showed that membership of the JSDH only was negatively related (odds ratio [OR] 0.28, 95% confidence interval [CI] 0.13–0.60), and use of behavioral therapy was positively related (OR 2.34, 95% CI 1.18–4.84) to the use of a questionnaire.

Conclusions
The results of this study showed that the use of questionnaires was very low, patients’ subjective opinions were commonly used to diagnose dental phobia, and a standardized diagnostic criterion was thus needed among practitioners. Therefore, it is necessary to establish diagnostic criteria for dental phobia in line with the Japanese clinical system and to educate dentists about them.
Medically-oriented design for explainable AI for stress prediction from physiological measurements
Authors: Jaber Dalia , Hajj Hazem , Maalouf Fadi , El-Hajj Wassim 
Published: February 2022

Abstract
Background
In the last decade, a lot of attention has been given to develop artificial intelligence (AI) solutions for mental health using machine learning. To build trust in AI applications, it is crucial for AI systems to provide for practitioners and patients the reasons behind the AI decisions. This is referred to as Explainable AI. While there has been significant progress in developing stress prediction models, little work has been done to develop explainable AI for mental health.

Methods
In this work, we address this gap by designing an explanatory AI report for stress prediction from wearable sensors. Because medical practitioners and patients are likely to be familiar with blood test reports, we modeled the look and feel of the explanatory AI on those of a standard blood test report. The report includes stress prediction and the physiological signals related to stressful episodes. In addition to the new design for explaining AI in mental health, the work includes the following contributions: Methods to automatically generate different components of the report, an approach for evaluating and validating the accuracies of the explanations, and a collection of ground truth of relationships between physiological measurements and stress prediction.

Results
Test results showed that the explanations were consistent with ground truth. The reference intervals for stress versus non-stress were quite distinctive with little variation. In addition to the quantitative evaluations, a qualitative survey, conducted by three expert psychiatrists confirmed the usefulness of the explanation report in understanding the different aspects of the AI system.

Conclusion
In this work, we have provided a new design for explainable AI used in stress prediction based on physiological measurements. Based on the report, users and medical practitioners can determine what biological features have the most impact on the prediction of stress in addition to any health-related abnormalities. The effectiveness of the explainable AI report was evaluated using a quantitative and a qualitative assessment. The stress prediction accuracy was shown to be comparable to state-of-the-art. The contributions of each physiological signal to the stress prediction was shown to correlate with ground truth. In addition to these quantitative evaluations, a qualitative survey with psychiatrists confirmed the confidence and effectiveness of the explanation report in the stress made by the AI system. Future work includes the addition of more explanatory features related to other emotional states of the patient, such as sadness, relaxation, anxiousness, or happiness.
Access to healthcare for street sex workers in the UK: perspectives and best practice guidance from a national cross-sectional survey of frontline workers
Authors: Potter Lucy C. , Horwood Jeremy , Feder Gene 
Published: February 2022

Abstract
Background
Street sex workers (SSWs) are a highly marginalised and stigmatised group who carry an extremely high burden of unmet health need. They experience multiple and interdependent health and social problems and extreme health inequality. Despite high levels of chronic physical and mental ill-health, there is little evidence of effective healthcare provision for this group. They are often considered ‘hard to reach’, but many individuals and organisations have extensive experience of working with this group.

Methods
We conducted a cross-sectional survey of professionals who work with SSWs in the UK on their perspectives on their access to primary care, mental health, sexual health and drug and alcohol services, how well these services met the needs of SSWs and suggestions of best practice.

Results
50 professionals mostly from England, responded. Mainstream general practice and mental health services were found to be largely inaccessible to SSWs. Sexual health, drug and alcohol services and homeless health services better met their needs; this was mostly attributed to flexible services and collaborations with organisations who work closely with SSWs. The main challenges in providing healthcare to SSWs were services being inflexible, under-resourced services and services not being trauma-informed. Best practice in providing healthcare to SSWs includes- seamless partnership working between agencies with case worker support; peer-involvement in service development and engagement, a range of health provision including outreach, presence in community spaces and fast-track access into mainstream services; trauma-informed, gender-sensitive health services in a welcoming environment with flexible, responsive appointment and drop-in systems and consistent clinicians with specialist knowledge of substance misuse, mental health, domestic violence and homelessness.

Conclusions
Access to healthcare for SSWs in the UK is highly variable but largely inadequate with regards to primary care and mental health provision. The examples of positive healthcare provision and partnership working presented here demonstrate the feasibility of accessible healthcare that meets the needs of SSWs. These need to be systematically implemented and evaluated to understand their impact and implications. As we build back from COVID-19 there is an urgent need to make accessible healthcare provision for marginalised groups the norm, not the exception.
c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial
Authors: Morgan Robert D. , Ferreras Cristina , Peset Isabel , Avizienyte Egle , Renehan Andrew G. , Edmondson Richard J. , Murphy Alexander D. , Nicum Shibani , Van Brussel Thomas , Clamp Andrew R. , Lambrechts Diether , Zhou Cong , Jayson Gordon C. 
Published: February 2022

Abstract
Introduction
Bevacizumab improves survival outcomes in women diagnosed with epithelial ovarian cancer (EOC). Pre-clinical data showed that the c-MET/VEGFR-2 heterocomplex negates VEGF inhibition through activation of c-MET signalling, leading to a more invasive and metastatic phenotype. We evaluated the clinical significance of c-MET and VEGFR-2 co-localisation and its association with VEGF pathway-related single nucleotide polymorphisms (SNPs) in women participating in the phase 3 trial, ICON7 (ClinicalTrials.gov identifier: NCT00262847).

Materials and methods
Patients had FIGO stage I-IIA grade 3/poorly differentiated or clear cell carcinoma or stage IIB-IV epithelial ovarian, primary peritoneal or fallopian tube cancer. Immunofluorescence staining for co-localised c-MET and VEGFR-2 on tissue microarrays and genotyping of germline DNA from peripheral blood leukocytes for VEGFA and VEGFR-2 SNPs was performed. The significance of these biomarkers was assessed against survival.

Results
Tissue microarrays from 178 women underwent immunofluorescence staining. Multivariable analysis showed that greater c-MET/VEGFR-2 co-localisation predicted worse OS in patients treated with bevacizumab after adjusting for FIGO stage and debulking surgery outcome (hazard ratio [HR] 1.034, 95% confidence interval [95%CI] 1.010–1.059). Women in the c-MET/VEGFR-2HIGH group treated with bevacizumab demonstrated significantly reduced OS (39.3 versus > 60 months; HR 2.00, 95%CI 1.08–3.72). Germline DNA from 449 women underwent genotyping. In the bevacizumab group, those women with the VEGFR-2 rs2305945 G/G variant had a trend towards shorter PFS compared with G/T or T/T variants (18.3 versus 23.0 months; HR 0.74, 95%CI 0.53–1.03).

Conclusions
In bevacizumab-treated women diagnosed with EOC, high c-MET/VEGFR-2 co-localisation on tumour tissue and the VEGFR-2 rs2305945 G/G variant, which may be biologically related, were associated with worse survival outcomes.
Stochastic integrated model-based protocol for volume-controlled ventilation setting
Authors: Lee Jay Wing Wai , Chiew Yeong Shiong , Wang Xin , Mat Nor Mohd Basri , Chase J. Geoffrey , Desaive Thomas 
Published: February 2022

Abstract
Background and objective
Mechanical ventilation (MV) is the primary form of care for respiratory failure patients. MV settings are based on general clinical guidelines, intuition, and experience. This approach is not patient-specific and patients may thus experience suboptimal, potentially harmful MV care. This study presents the Stochastic integrated VENT (SiVENT) protocol which combines model-based approaches of the VENT protocol from previous works, with stochastic modelling to take the variation of patient respiratory elastance over time into consideration.

Methods
A stochastic model of Ers is integrated into the VENT protocol from previous works to develop the SiVENT protocol, to account for both intra- and inter-patient variability. A cohort of 20 virtual MV patients based on retrospective patient data are used to validate the performance of this method for volume-controlled (VC) ventilation. A performance evaluation was conducted where the SiVENT and VENT protocols were implemented in 1080 instances each to compare the two protocols and evaluate the difference in reduction of possible MV settings achieved by each.

Results
From an initial number of 189,000 possible MV setting combinations, the VENT protocol reduced this number to a median of 10,612, achieving a reduction of 94.4% across the cohort. With the integration of the stochastic model component, the SiVENT protocol reduced this number from 189,000 to a median of 9329, achieving a reduction of 95.1% across the cohort. The SiVENT protocol reduces the number of possible combinations provided to the user by more than 1000 combinations as compared to the VENT protocol.

Conclusions
Adding a stochastic model component into a model-based approach to selecting MV settings improves the ability of a decision support system to recommend patient-specific MV settings. It specifically considers inter- and intra-patient variability in respiratory elastance and eliminates potentially harmful settings based on clinically recommended pressure thresholds. Clinical input and local protocols can further reduce the number of safe setting combinations. The results for the SiVENT protocol justify further investigation of its prediction accuracy and clinical validation trials.
Pan-cancer quantitation of epithelial-mesenchymal transition dynamics using parallel reaction monitoring-based targeted proteomics approach
Authors: Jain Ankit P. , Sambath Janani , Sathe Gajanan , George Irene A. , Pandey Akhilesh , Thompson Erik W. , Kumar Prashant 
Published: February 2022

AbstractEpithelial–mesenchymal transition (EMT) is a dynamic and complex cellular process that is known to be hijacked by cancer cells to facilitate invasion, metastasis and therapeutic resistance. Several quantitative measures to assess the interplay between EMT and cancer progression are available, based on large scale genome and transcriptome data. However, these large scale multi-omics studies have repeatedly illustrated a lack of correlation in mRNA and protein abundances that may be influenced by diverse post-translational regulation. Hence, it is imperative to understand how changes in the EMT proteome are associated with the process of oncogenic transformation. To this effect, we developed a parallel reaction monitoring-based targeted proteomics method for quantifying abundances of EMT-associated proteins across cancer cell lines. Our study revealed that quantitative measurement of EMT proteome which enabled a more accurate assessment than transcriptomics data and revealed specific discrepancies against a backdrop of generally strong concordance between proteomic and transcriptomic data. We further demonstrated that changes in our EMT proteome panel might play a role in tumor transformation across cancer types. In future, this EMT panel assay has the potential to be used for clinical samples to guide treatment choices and to congregate functional information for the development and advancing novel therapeutics.
The role of S100B/RAGE-enhanced ADAM17 activation in endothelial glycocalyx shedding after traumatic brain injury
Authors: Zou Zhimin , Li Li , Li Qin , Zhao Peng , Zhang Kun , Liu Chengyong , Cai Daozhang , Maegele Marc , Gu Zhengtao , Huang Qiaobing 
Published: February 2022

Abstract
Background
Traumatic brain injury (TBI) remains one of the main causes for disability and death worldwide. While the primary mechanical injury cannot be avoided, the prevention of secondary injury is the focus of TBI research. Present study aimed to elucidate the effects and mechanisms of S100B and its receptor RAGE on mediating secondary injury after TBI.

Methods
This study established TBI animal model by fluid percussion injury in rats, cell model by stretch-injured in astrocytes, and endothelial injury model with conditioned medium stimulation. Pharmacological intervention was applied to interfere the activities of S100B/RAGE/ADAM17 signaling pathway, respectively. The expressions or contents of S100B, RAGE, syndecan-1 and ADAM17 in brain and serum, as well as in cultured cells and medium, were detected by western blot. The distribution of relative molecules was observed with immunofluorescence.

Results
We found that TBI could activate the release of S100B, mostly from astrocytes, and S100B and RAGE could mutually regulate their expression and activation. Most importantly, present study revealed an obvious increase of syndecan-1 in rat serum or in endothelial cultured medium after injury, and a significant decrease in tissue and in cultured endothelial cells, indicating TBI-induced shedding of endothelial glycocalyx. The data further proved that the activation of S100B/RAGE signaling could promote the shedding of endothelial glycocalyx by enhancing the expression, translocation and activity of ADAM17, an important sheddase, in endothelial cells. The damage of endothelial glycocalyx consequently aggravated blood brain barrier (BBB) dysfunction and systemic vascular hyper-permeability, overall resulting in secondary brain and lung injury.

Conclusions
TBI triggers the activation of S100B/RAGE signal pathway. The regulation S100B/RAGE on ADAM17 expression, translocation and activation further promotes the shedding of endothelial glycocalyx, aggravates the dysfunction of BBB, and increases the vascular permeability, leading to secondary brain and lung injury. Present study may open a new corridor for the more in-depth understanding of the molecular processes responsible for cerebral and systemic vascular barrier impairment and secondary injury after TBI.
Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series
Authors: Minkove Samuel J. , Geiger Grant , Llibre Josep M. , Montgomery Mary W. , West Natalie E. , Chida Natasha M. , Antar Annukka A. R. , Dandachi Dima , Weld Ethel D. ,   HIV-COVID-19 Consortium, Karmen-Tuohy Savannah , Carlucci Philip M. , Zacharioudakis Ioannis M. , Rahimian Joseph , Zervou Fainareti N. , Rebick Gabriel , Stachel Anna , Tang Shini , Ding Dan , Jones Joyce L. , Farley Jason E. , Dooley Kelly E. , Wilgus Barbara E. , Sanchez Michael , Chow Jeremy , Kitchell Ellen , Koh Shannon , Maxwell Daniel , Lau Abby , Brooks Shamika , Chu Jessica , Estrada Joshua , Lazarte Susana M. , Arinze Folasade , Francis Adero , Paranjape Neha , Sax Paul E. , Wanjalla Celestine N. , Kheshti Asghar N. , Bailin Samuel , Koethe John , Kelly Sean G. , Raffanti Stephen P. , Patel Shital M. , Xu Teena Huan , Goebel Melanie , Santiago Alberto Díaz-De , Ray Manoj , Slim Jihad , Kratz Ann Marie Porreca , Koren David E. , Hiryak Kayla , Hill Brannon , Dare Ryan K. , Bordelon Stacie , Bailey Brett , Baddley John W. , Matthew Shoemaker D. , Rodriguez-Nava Guillermo , Shweta F. N. U. , Chu Carolyn , Pearson Catherine , Treakle Amy , Furin Jennifer J. , Bogorodskaya Milana , Desai Samit , Osterholzer Danielle , Arquiette Jered , Ford Emily S. , Ching Patrick R. , Sun Louisa , Buggy Brian P. , Tirmizi Amir , Argentine Sarah , Desai Balaji , Swartz Talia H. , Latimer Dusty , Camazine Maraya 
Published: February 2022

Abstract
Background
In hospitalized people with HIV (PWH) there is an increased risk of mortality from COVID-19 among hospitalized PWH as compared to HIV-negative individuals. Evidence suggests that tocilizumab—a humanized monoclonal interleukin (IL)-6 receptor inhibitor (IL-6ri) antibody—has a modest mortality benefit when combined with corticosteroids in select hospitalized COVID-19 patients who are severely ill. Data on clinical outcomes after tocilizumab use in PWH with severe COVID-19 are lacking.

Case presentation
We present a multinational case series of 18 PWH with COVID-19 who were treated with IL-6ri’s during the period from April to June 2020. Four patients received tocilizumab, six sarilumab, and eight received an undocumented IL-6ri. Of the 18 patients in the series, 4 (22%) had CD4 counts < 200 cells/mm3; 14 (82%) had a suppressed HIV viral load. Eight patients (44%), all admitted to ICU, were treated for secondary infection; 5 had a confirmed organism. Of the four patients with CD4 counts < 200 cells/mm3, three were treated for secondary infection, with 2 confirmed organisms. Overall outcomes were poor—12 patients (67%) were admitted to the ICU, 11 (61%) required mechanical ventilation, and 7 (39%) died.

Conclusions
In this case series of hospitalized PWH with COVID-19 and given IL-6ri prior to the common use of corticosteroids, there are reports of secondary or co-infection in severely ill patients. Comprehensive studies in PWH, particularly with CD4 counts < 200 cells, are warranted to assess infectious and other outcomes after IL-6ri use, particularly in the context of co-administered corticosteroids.
The diagnostic levels of evidence of instrumented devices for measuring viscoelastic joint properties and spasticity; a systematic review
Authors: van der Velden Levinia Lara , de Koff Maaike Anna Catharina , Ribbers Gerard Maria , Selles Ruud Willem 
Published: February 2022

Abstract
Background
Many diagnostic robotic devices have been developed to quantify viscoelastic properties and spasticity of patients with upper motor neuron lesions. However, in clinical practice, subjective and nonvalid clinical scales are still commonly used. To understand the limited use of diagnostic robotic devices assessing viscoelastic joint properties and spasticity in clinical practice, we evaluate the diagnostic level of evidence of studies on these devices.

Method
A systematic literature review was performed using multiple databases. Two of the authors independently screened all articles. Studies investigating human subjects diagnosed with stroke or cerebral palsy, measured with a mechanical device to assess viscoelastic joint properties and/or spasticity of an extremity. All articles were assigned a diagnostic level of evidence, which was established with a classification strategy based on the number of participants and the design of the study, from a Level 0 (less than 10 subjects) to a Level IV, reporting the long-term clinical consequences in daily care.

Results
Fifty-nine articles were included. Most studies measured the upper limb (64%) in stroke patients (81%). The highest level of evidence found was Level IIa (53%); these studies correlated the test values of the robotic device with a clinical test or within subgroups. Level 0 (30%) and Level I (17%; determining the range of values of the robotic test) were also common. None of the studies tested their device for diagnostic accuracy (Level III), clinical added value (Level IV).

Conclusion
The diagnostic evidence needed for implementing robotic devices in clinical practice is lacking. Our findings indicate that more effort should be invested in studying diagnostic accuracy (Level III) or added value for clinical care (Level IV); only these studies can provide clinicians with evidence that robotic devices have added value above the currently-used clinical scales.